By using this site, you agree to the Privacy Policy and Terms of Use.

CANCER IDENTIFICATION
Healthcare Technology August 22, 2022

Evolution of Biopsies in Cancer Identification

Healthcare Technology August 18, 2022

The Growth of Digital Health –

Biomarkers
Healthcare Pharma Technology August 9, 2022

Biomarkers & Their Increasingly Crucial Role

Tower B5, Office 101, Magarpatta SEZ Hadapsar, Pune-411013, India

+91 20 48598285

[email protected]

MarketsandMarkets Conferences > Blog > antibodies
2nd Annual MarketsandMarkets Next Gen Immuno Oncology Congress Healthcare News Pharma

Speaker Inerview with William Williams for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 10, 2019 – MarketsandMarkets recently interviewed William Williams, President, CEO BriaCell Corporation regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City.  Q. What are the recent advances in the immune-oncology and current challenges that need immediate attention? A. The major advance […]

Read More
2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congres Healthcare News Pharma

Speaker Inerview with Emmanuel Normant for 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress

Philadelphia, USA August 09, 2019 – MarketsandMarkets recently interviewed Emmanuel Normant, Vice President, Preclinical Sciences, TG Therapeutics regarding the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress, taking place on September 19 – 20, 2019 at Hilton Garden Inn Philadelphia Center City. Emmanuel Normant is vice president of preclinical sciences at TG Therapeutics, a clinical-stage biotech company focused on hematologic cancers and […]

Read More
Next Gen Immuno Oncology Congress Healthcare News Pharma Uncategorized

Genmab Partners Raised $503M U.S. IPO on Cancer Antibodies with BliNK Biomedical

Genmab through collaboration with Blink biomedicals raised a whopping $503 Million through an American initial public offering (IPO) all this got revealed on Friday during an event. Genmab also launched an up to $200 million-per-product cancer therapy with Blink biomedicals. Blink biomedicals got a license approved by Genmab exclusively for antibodies targeting CD47, which Genmab […]

Read More